These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15347084)

  • 1. [Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction].
    MMW Fortschr Med; 2004 Mar; 146(10):44. PubMed ID: 15347084
    [No Abstract]   [Full Text] [Related]  

  • 2. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
    Warren KR; Buchanan RW; Feldman S; Conley RR; Linthicum J; Ball MP; Liu F; McMahon RP; Gorelick DA; Huestis MA; Kelly DL
    J Clin Psychopharmacol; 2013 Feb; 33(1):118-20. PubMed ID: 23277241
    [No Abstract]   [Full Text] [Related]  

  • 7. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.
    Pagotto U; Pasquali R
    Lancet; 2005 Apr 16-22; 365(9468):1363-4. PubMed ID: 15836868
    [No Abstract]   [Full Text] [Related]  

  • 9. ADAGIO-Lipids gives promises but faces the setbacks.
    Taskinen MR
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].
    Kvasnicka T
    Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic risk modification: current trends and emerging therapies.
    Lillo JL; Bray G; Woods SC; Henry RR; Hadley RD
    JAAPA; 2006 Dec; Suppl Cardiometabolic():3-14; quiz 15-6. PubMed ID: 17354517
    [No Abstract]   [Full Text] [Related]  

  • 14. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
    Cota D; Genghini S; Pasquali R; Pagotto U
    J Endocrinol Invest; 2003 Oct; 26(10):1041-4. PubMed ID: 14759080
    [No Abstract]   [Full Text] [Related]  

  • 17. Cannabinoid CB1 receptors control conditioned drug seeking.
    De Vries TJ; Schoffelmeer AN
    Trends Pharmacol Sci; 2005 Aug; 26(8):420-6. PubMed ID: 15992935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimonabant Sanofi-Synthélabo.
    Fernandez JR; Allison DB
    Curr Opin Investig Drugs; 2004 Apr; 5(4):430-5. PubMed ID: 15134285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
    Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
    Banasch M; Goetze O; Schmidt WE; Meier JJ
    Liver Int; 2007 Oct; 27(8):1152-5. PubMed ID: 17845546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.